Schond L. Greenway

Chief Financial Officer, Avalo Therapeutics, Inc.

Companies

Definium TherapeuticsChief financial officer May 23, 2022 to Mar 26, 2024¹
Avalo Therapeutics, Inc.Chief financial officer Mar 1, 2021 to Dec 14, 2021²

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

As of each latest filing. The line shows shares held over time.

Mar 25, 2024Shares withheld for tax 5,560 shares at $9.78 of Definium Therapeutics³
Dec 26, 2023Sold 5,652 shares at $3.63 of Definium Therapeutics⁵
Sep 25, 2023Sold 3,854 shares at $3.58 of Definium Therapeutics⁶
Sep 25, 2023Sold 1,908 shares at $3.57 of Definium Therapeutics⁶
Aug 25, 2023Sold 20,000 shares at $3.80 of Definium Therapeutics⁷
Jun 27, 2023Sold 3,941 shares at $3.21 of Definium Therapeutics⁸
Jun 27, 2023Sold 7,694 shares at $3.19 of Definium Therapeutics⁸
Mar 14, 2023Granted 175,000 shares of Definium Therapeutics⁹
Mar 14, 2023Granted 175,000 shares of Definium Therapeutics¹⁰
May 23, 2022Granted 1,270,000 shares of Definium Therapeutics¹¹
May 23, 2022Granted 1,270,000 shares of Definium Therapeutics¹²
Dec 10, 2021Bought 2,231 shares at $1.57 of Avalo Therapeutics, Inc.⁴

The numbers on this page point here. Each one links to the record it came from.